Correlation Between SIVERS SEMICONDUCTORS and Brainstorm Cell

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both SIVERS SEMICONDUCTORS and Brainstorm Cell at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining SIVERS SEMICONDUCTORS and Brainstorm Cell into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between SIVERS SEMICONDUCTORS AB and Brainstorm Cell Therapeutics, you can compare the effects of market volatilities on SIVERS SEMICONDUCTORS and Brainstorm Cell and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in SIVERS SEMICONDUCTORS with a short position of Brainstorm Cell. Check out your portfolio center. Please also check ongoing floating volatility patterns of SIVERS SEMICONDUCTORS and Brainstorm Cell.

Diversification Opportunities for SIVERS SEMICONDUCTORS and Brainstorm Cell

0.66
  Correlation Coefficient

Poor diversification

The 3 months correlation between SIVERS and Brainstorm is 0.66. Overlapping area represents the amount of risk that can be diversified away by holding SIVERS SEMICONDUCTORS AB and Brainstorm Cell Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Brainstorm Cell Ther and SIVERS SEMICONDUCTORS is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on SIVERS SEMICONDUCTORS AB are associated (or correlated) with Brainstorm Cell. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Brainstorm Cell Ther has no effect on the direction of SIVERS SEMICONDUCTORS i.e., SIVERS SEMICONDUCTORS and Brainstorm Cell go up and down completely randomly.

Pair Corralation between SIVERS SEMICONDUCTORS and Brainstorm Cell

Assuming the 90 days horizon SIVERS SEMICONDUCTORS AB is expected to under-perform the Brainstorm Cell. In addition to that, SIVERS SEMICONDUCTORS is 2.81 times more volatile than Brainstorm Cell Therapeutics. It trades about -0.12 of its total potential returns per unit of risk. Brainstorm Cell Therapeutics is currently generating about -0.14 per unit of volatility. If you would invest  351.00  in Brainstorm Cell Therapeutics on September 13, 2024 and sell it today you would lose (82.00) from holding Brainstorm Cell Therapeutics or give up 23.36% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy89.06%
ValuesDaily Returns

SIVERS SEMICONDUCTORS AB  vs.  Brainstorm Cell Therapeutics

 Performance 
       Timeline  
SIVERS SEMICONDUCTORS 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days SIVERS SEMICONDUCTORS AB has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders.
Brainstorm Cell Ther 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Brainstorm Cell Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's fundamental indicators remain nearly stable which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders.

SIVERS SEMICONDUCTORS and Brainstorm Cell Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with SIVERS SEMICONDUCTORS and Brainstorm Cell

The main advantage of trading using opposite SIVERS SEMICONDUCTORS and Brainstorm Cell positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if SIVERS SEMICONDUCTORS position performs unexpectedly, Brainstorm Cell can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Brainstorm Cell will offset losses from the drop in Brainstorm Cell's long position.
The idea behind SIVERS SEMICONDUCTORS AB and Brainstorm Cell Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.

Other Complementary Tools

ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Fundamental Analysis
View fundamental data based on most recent published financial statements
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance